• Provides information for clinically actionable genomic alterations and their associatedtargeted therapy, both approved and in clinical trials.
• Evaluates TMB and MSl to better inform immunotherapy decisions.
• Predicts efhcacy and toxicity of chemotherapy based on associated genetic biomarkers.
• Reveals potential resistance mechanism(s) to current therapies and options foralternative treatments.
• Assesses genetic predisposition to certain cancer types for early intervention.
• Information about the likely outcome of disease (your patients’ prognosis).

• National Comprehensive Cancer Network (NCCN^®) guidance reflects more recent Food and Drug Administration (FDA) approvals of targeted therapies. They recommend testing solid tumor  specimens for genomic variants and biomarkers that could potentially offer effective therapeutic options. Gene selection and product design are carried out in conjunction with authoritative journals such as NEJM and JCO.
• Many of these variants serve as predictive biomarkers for response to targeted therapies and immunotherapies. High TMB (TMB-H) and MSI (MSI-H) are predictive biomarkers of response to treatment with immune checkpoint inhibitors.

People with solid tumors whose diagnosis, prognosis, or treatment selection could be informed by the presence of genomic variants and MSI/TMB status.

The AcornOne808 analyzes genes primarily associated with onset conditions across major organ systems, including but not limited to lung, breast, gynecologic (ovarian, uterine/endometrial), gastrointestinal (colorectal, gastric, pancreatic), thyroid, genitourinary (renal/urinary tract, prostate), melanoma, and so on. Sequencing of over 800 genes, identified as relevant to cancer treatment, as well as testing of important immunotherapy biomarkers provides a comprehensive picture for the oncologist to formulate a treatment plan with their patients.

• CE-approved test
• Covering genomic regions of 808 genes
• Uses hybrid capture-based next-generation sequencing (NGS)
• Identifies the four main classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations, and fusions